Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica

Multiple Sclerosis Journal

Volumn 19, Issue 7, 2013, Pages 926-931

  Wang, Honghao ^a,b   Wang, Kai ^b   Wang, Conghui ^b   Zhong, Xiaonan ^a   Qiu, Wei ^a   Hu, Xueqiang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

EDSS; inflammation; multiple sclerosis; neuromyelitis optica; Pentraxin 3; relapse

Indexed keywords

BIOLOGICAL MARKER; PENTRAXIN 3;

ADULT; ARTICLE; BRAIN INFARCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HEADACHE; HUMAN; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; RELAPSE; REMISSION;

EID: 84878352305     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512457845     Document Type: Article

References (32)

1. de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler. 2007 ; 13: 915-928
2. Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, Du Pasquier RA, Polman CH, Sorensen PS, Hemmer B. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010 ; 17: 1019-1032
3. Kira J. Neuromyelitis optica and asian phenotype of multiple sclerosis. Ann N Y Acad Sci. 2008 ; 1142: 58-71
4. Fujihara K, Nakashima I, Misu T, Fujimori J, Feng J, Sato S, Miyazawa I, Itoyama Y. Pathogenesis of optic-spinal MS. Rinsho Shinkeigaku. 2002 ; 42: 1195-1197
5. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE, Lassmann H. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002 ; 125: 1450-1461
6. Chataway J, Miller DH. Multiple sclerosis-quenching the flames of inflammation. Lancet. 2011 ; 378: 1759-1760
7. D'haeseleer M, Cambron M, Vanopdenbosch L, De Keyser J. Vascular aspects of multiple sclerosis. Lancet Neurol. 2011 ; 10: 657-666
8. Maekawa Y, Nagai T, Anzai A. Pentraxins CRP and PTX3 and cardiovascular disease. Inflamm Allergy Drug Targets. 2011 ; 10: 229-235
9. Mantovani A, Garlanda C, Doni A, Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol. 2008 ; 28: 1-13
10. Bottazzi B, Garlanda C, Cotena A, Moalli F, Jaillon S, Deban L, Mantovani A. The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. Immunol Rev. 2009 ; 227 (1). 9-18
11. Huttunen R, Hurme M, Aittoniemi J, Huhtala H, Vuento R, Laine J, Jylhävä J, Syrjänen J. High plasma level of long pentraxin 3 (PTX3) is associated with fatal disease in bacteremic patients: a prospective cohort study. PLoS One. 2011 ; 6 (3). e17653
12. Dubin R, Li Y, Ix JH, Shlipak MG, Whooley M, Peralta CA. Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study. Am Heart J. 2012 ; 163: 274-279
13. Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, Martinez de la Torre Y, Latini R. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol. 2006 ; 45: 326-330
14. Alles VV, Bottazzi B, Peri G, Golay J, Introna M, Mantovani A. Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood. 1994 ; 84: 3483-3493
15. Basile A, Sica A, d'Aniello E, Breviario F, Garrido G, Castellano M, Mantovani A, Introna M. Characterization of the promoter for the human long pentraxin PTX3: Role of NF-kappaB in tumor necrosis factor-alpha and interleukin-1beta regulation. J Biol Chem. 1997 ; 272: 8172-8178
16. Inforzato A, Rivieccio V, Morreale AP, Bastone A, Salustri A, Scarchilli L, Verdoliva A, Vincenti S, Gallo G, Chiapparino C, Pacello L, Nucera E, Serlupi-Crescenzi O, Day AJ, Bottazzi B, Mantovani A, De Santis R, Salvatori G. Structural characterization of PTX3 disulfide bond network and its multimeric status in cumulus matrix organization. J Biol Chem. 2008 ; 283: 10147-10161
17. Savchenko AS, Inoue A, Ohashi R, Jiang S, Hasegawa G, Tanaka T, Hamakubo T, Kodama T, Aoyagi Y, Ushiki T, Naito M. Long pentraxin 3 (PTX3) expression and release by neutrophils in vitro and in ulcerative colitis. Pathol Int. 2011 ; 61: 290-297
18. Inoue K, Kodama T, Daida H. Pentraxin 3: a novel biomarker for inflammatory cardiovascular disease. Int J Vasc Med. 2012 ; 2012: 657025
19. Hampel DJ, Pratschke J, May G, Reinke P, Schindler R. Living kidney donation: anemia and inflammation in the early postoperative period. Transplant Proc. 2006 ; 38: 661-663
20. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, Vago L, Pasqualini F, Signorini S, Soldateschi D, Tarli L, Schweiger C, Fresco C, Cecere R, Tognoni G, Mantovani A. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004 ; 110: 2349-2354
21. Luchetti MM, Piccinini G, Mantovani A, Peri G, Matteucci C, Pomponio G, Fratini M, Fraticelli P, Sambo P, Di Loreto C, Doni A, Introna M, Gabrielli A. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). Clin Exp Immunol. 2000 ; 119: 196-202
22. Lee HW, Choi J, Suk K. Increases of pentraxin 3 plasma levels in patients with Parkinson's disease. Mov Disord. 2011 ; 26: 2364-2370
23. Zanier ER, Brandi G, Peri G, Longhi L, Zoerle T, Tettamanti M, Garlanda C, Sigurtà A, Valaperta S, Mantovani A, De Simoni MG, Stocchetti N. Cerebrospinal fluid pentraxin 3 early after subarachnoid hemorrhage is associated with vasospasm. Intensive Care Med. 2011 ; 37: 302-309
24. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 ; 69: 292-302
25. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 ; 66: 1485-1489
26. Lassmann H. Mechanisms of inflammation induced tissue injury in multiple sclerosis. J Neurol Sci. 2008 ; 274 (1-2). 45-47
27. Popescu BF, Lucchinetti CF. Pathology of demyelinating diseases. Annu Rev Pathol. 2012 ; 7: 185-217
28. CieÅlik P, Hrycek A. Long pentraxin 3 (PTX3) in the light of its structure, mechanism of action and clinical implications. Autoimmunity. 2012 ; 45: 119-128
29. Guo T, Ke L, Qi B, Wan J, Ge J, Bai L, Cheng B. PTX3 Is Located at the Membrane of Late Apoptotic Macrophages and Mediates the Phagocytosis of Macrophages. J Clin Immunol. 2012 ; 32: 330-339
30. Jaillon S, Peri G, Delneste Y, Frémaux I, Doni A, Moalli F, Garlanda C, Romani L, Gascan H, Bellocchio S, Bozza S, Cassatella MA, Jeannin P, Mantovani A. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med. 2007 ; 204 (4). 793-804
31. Thouvenot E, Lafon-Cazal M, Demettre E, Jouin P, Bockaert J, Marin P. The proteomic analysis of mouse choroid plexus secretome reveals a high protein secretion capacity of choroidal epithelial cells. Proteomics. 2006 ; 6: 5941-5952
32. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol. 2010 ; 6: 383-392